Shire PLC’s (SHPG) “Buy” Rating Reiterated at Citigroup Inc.
Several other equities research analysts also recently issued reports on SHPG. Morgan Stanley reissued an overweight rating on shares of Shire PLC in a research report on Friday, June 3rd. Jefferies Group increased their price objective on shares of Shire PLC from $223.00 to $262.00 and gave the stock a buy rating in a research report on Friday, June 3rd. Zacks Investment Research downgraded shares of Shire PLC from a buy rating to a hold rating in a research report on Wednesday, June 8th. Sanford C. Bernstein reissued an outperform rating and set a $222.00 price objective on shares of Shire PLC in a research report on Thursday, June 9th. Finally, Piper Jaffray Cos. reissued a neutral rating and set a $174.00 price objective on shares of Shire PLC in a research report on Monday, June 13th. Five research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. Shire PLC currently has an average rating of Buy and a consensus target price of $230.67.
Shares of Shire PLC (NASDAQ:SHPG) opened at 194.82 on Tuesday. Shire PLC has a one year low of $147.60 and a one year high of $231.32. The company has a 50-day moving average price of $196.27 and a 200 day moving average price of $185.51. The firm has a market capitalization of $58.03 billion, a P/E ratio of 40.49 and a beta of 1.11.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the prior year, the firm earned $2.63 earnings per share. The firm’s revenue was up 55.9% compared to the same quarter last year. Analysts expect that Shire PLC will post $12.93 earnings per share for the current fiscal year.
The business also recently announced a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be paid a dividend of $0.139 per share. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio is presently 15.63%.
Hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Shire PLC during the fourth quarter valued at $31,671,000. BTC Capital Management Inc. boosted its stake in shares of Shire PLC by 12.5% in the first quarter. BTC Capital Management Inc. now owns 1,213 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 135 shares during the period. Exane Asset Management acquired a new stake in shares of Shire PLC during the first quarter valued at $12,851,000. Ngam Advisors L.P. boosted its stake in shares of Shire PLC by 22.8% in the first quarter. Ngam Advisors L.P. now owns 34,151 shares of the biopharmaceutical company’s stock valued at $5,870,000 after buying an additional 6,333 shares during the period. Finally, Connable Office Inc. boosted its stake in shares of Shire PLC by 17.5% in the first quarter. Connable Office Inc. now owns 2,205 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 328 shares during the period. Institutional investors own 24.26% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.